Genicular Nerve Phenol Neurolysis Versus Radiofrequency Ablation for Pain Relief in Grade 4 Knee Osteoarthritis

N/ANot Yet RecruitingNCT06864390

Ain Shams University114 enrolled

Overview

The goal of this clinical trial is to compare the efficiency and efficacy of genicular nerves blockade by chemical phenol neurolysis versus radiofrequency ablation in managing pain in patients suffering from grade IV KOA in term of NRS pain score. The participants will be evaluated by numeric rating scale and oxford knee score for assessment of pain relief up to 16 weeks.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

114

Conditions

Joint Pain

Interventions

genicular nerve neurolysisPROCEDURE

The superior medial genicular nerve (SMGN), superior lateral genicular nerve (SLGN), and inferior medial genicular nerve (IMGN) will be blocked either by phenol neurolysis or radiofrequency ablation

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Grade 4 knee osteoarthritis according to Kellgren-Lawrence radiological classification. * Failure to manage pain with conservative methods. Exclusion Criteria: * Prior knee replacement * Patients with cardiac pacemakers or implantable cardiac defibrillators. * Septic knee or systemic sepsis. * Allergy to any of the drugs used in the study. * Coagulopathy or patients on anticoagulants. * Patients with psychiatric illness.

Outcomes

Primary Outcomes

Numeric rating scale

By an independent physician pain will be recorded using numeric rating scale which is a screening tool used to assess pain severity using a 0 - 10 scale with zero meaning no pain and 10 meaning the worst pain ever.

Time frame: baseline, 2, 4, 8,12 and 16 weeks after the procedure

Secondary Outcomes

oxford knee score

This score is used to assess both function and pain of the knee on a scale ranging from 0 (worst pain and function) and 48 (best function and no pain) this score will be recorded by an independent physician

Time frame: baseline, 4, 8, 12, 16 weeks after the procedure

Central Contacts

ahmed boeith, MD

CONTACT

02001003074795 ahmedabdelrahamn2008@med.asu.edu.eg

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.